Every APOE4 trial, readable.
Each trial from ClinicalTrials.gov, translated into plain English with our read on what it means for carriers. Free, no signup.
Every protocol translated from trial-speak into sentences a human reads once.
A verdict per trial: does your genotype get you in, keep you out, or change the risk.
Synced from ClinicalTrials.gov every day, so a closed trial never wastes your call.
1,349 of 1,349 APOE4 trials match — showing the first 60
Study on Biomarkers for Early Diagnosis of Alzheimer's Disease
This is an observational study based in China that is tracking elderly people over five years to identify early biological markers of Alzheimer's disease. Researchers are collecting blood, genetic, and brain imaging data across a range of participants — from cognitively normal to diagnosed AD — hoping to build better early-detection tools and a model that predicts five-year risk. No phase is listed because no drug or device is being tested.
China Cognition and Aging Study
This is a large observational study based in China, not a drug or treatment trial. Researchers are building a national database by following thousands of people over time, tracking who develops memory problems or dementia, collecting brain scans, blood samples, and genetic data. The goal is to understand how dementia unfolds in Chinese populations. There is no Phase designation because nothing is being tested for approval — this is research groundwork.
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
This trial is testing whether a supplement called nicotinamide riboside (a form of vitamin B3) produces measurable changes in brain energy metabolism in people with mild cognitive impairment or mild Alzheimer's dementia. Researchers are using a passive home sensor device to track digital biomarkers — things like sleep, movement, and breathing patterns — rather than clinic visits alone. The phase is unspecified, so the scale and stage of testing are unclear from the available information.
Predicting Pre-dementia
This observational study is testing whether a multimodal prediction model — combining genetic risk scores, blood biomarkers, health record data, and wearable device readings — can accurately forecast who will progress to early MCI within two years. There is no drug or treatment involved. It is observational, meaning researchers are watching and measuring, not intervening. Think of it as a sophisticated early-warning system study.
Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
This trial is testing KDS2010, an experimental oral drug taken once daily, in people who have early Alzheimer's-related memory problems — either mild cognitive impairment or mild dementia confirmed by amyloid PET scan. Researchers are comparing two doses against a placebo to see whether it improves cognition, daily functioning, and biomarkers over 24 weeks. This is a Phase 2a trial, meaning it is an early test of whether the drug works and is safe — not proven or approved.
Sleep Impairment in Subjects at Risk of Developing Alzheimer's Disease
This study is observing whether poor sleep is linked to cognitive decline in people at early risk of Alzheimer's. Participants undergo sleep studies, cognitive testing, and biomarker checks — no experimental drug is involved. It is a non-interventional, observational study, meaning researchers are watching and measuring, not treating. The goal is to understand whether sleep problems predict or accelerate cognitive decline, which could eventually point toward earlier intervention.
Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease
This trial is testing whether infusing stem-like cells from donated umbilical cord blood — on top of a standard Alzheimer's drug — is safe and shows early signs of benefit in people with mild to moderate Alzheimer's. It is an Early Phase 1 trial, meaning the primary goal is safety and finding the right dose, not proving the treatment works. Thirty patients are divided into two dose groups and one placebo group, then followed for six months.
Comparison of Two Non-invasive Neuromodulation Techniques as Synergistic Therapy to Cognitive Stimulation in Amnestic Mild Cognitive Impairment (aMCI)
This trial is testing two types of non-invasive brain stimulation — repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) — each paired with structured cognitive exercises, in people with amnestic mild cognitive impairment. Researchers want to see which combination best supports memory and brain function. This is a Phase NA (feasibility or exploratory) trial, meaning it is designed to gather early data, not to prove a treatment works definitively.
Is the CRP-Albumin-Lymphocyte (CALLY) Index Effective in Predicting Postoperative Delirium in Geriatric Patients Undergoing Hip Fracture Surgery
This study is testing whether a simple blood-test index called the CALLY Index, which combines three routine lab values, CRP, albumin, and lymphocyte count, can predict which elderly hip fracture patients will develop delirium after surgery. It is an observational study, not a treatment trial, meaning researchers are watching and measuring rather than giving any new therapy. Details on formal phase designation are not provided.
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
This trial is studying how social isolation and social interaction affect the brain and the risk of progressing from subjective cognitive decline to more serious memory problems. Researchers will use observational studies and a randomized controlled trial to track participants over time and test whether staying socially connected protects brain function. The phase is unspecified, meaning it is exploratory research rather than a standard drug-testing trial.
Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease
This trial tests two versions of a healthy-living education program aimed at helping middle-aged adults make lasting lifestyle changes — better diet, more physical activity, stress management, and mental engagement. Researchers want to know which approach works better for sustaining those changes over time. It is a Phase NA (non-drug, behavioral) study, meaning it is testing whether the program works, with no experimental medication involved.
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
This trial is testing a new PET scan tracer called [18F]RP-115, which is designed to image a protein called EAAT2 — a glutamate transporter found on brain cells called astrocytes. The goal is to see whether this tracer is safe in humans and whether it can detect early brain changes in Alzheimer's disease and frontotemporal dementia. This is a Phase 1 trial, meaning it is the very first time this imaging agent is being used in people.
The Chinese Familial Alzheimer's Network
This is a Chinese registry and research network, not a treatment trial. Researchers are enrolling families with hereditary Alzheimer's disease caused by known gene mutations to collect data on genetics, brain imaging, and biomarkers. The goal is to build a national database and better understand how familial Alzheimer's develops over time. No phase is listed because no drug or intervention is being tested — this is observational research.
Effect of Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis in Patients With Intracranial Lymphatic Circulation Disorder
This trial is testing a surgical procedure called lymphaticovenous anastomosis — tiny connections made between lymphatic vessels and veins in the neck — to see whether it improves brain waste clearance and cognitive function in people with Alzheimer's disease. It is a Phase NA study, meaning this is early exploratory work assessing whether the procedure is feasible and shows any effect, not yet proven or approved.
Adapting RDAD for DS
This trial is testing a remote exercise and caregiver education program adapted for older adults with Down syndrome, who face a very high lifetime risk of Alzheimer's disease. Researchers want to see whether the program is practical to deliver and shows early signs of benefit. It is a feasibility study — a Phase N/A design meant to assess whether a larger, more definitive trial is worth running.
Taiwan Post-Stroke Disability Study
This is an observational study, not a treatment trial. Researchers in Taiwan are enrolling 2,000 stroke patients and following them for one year to track disabilities that develop after stroke — including memory problems, depression, swallowing difficulties, and seizures. There is no drug or intervention being tested. The goal is to better understand how common these problems are and what risk factors drive them. No phase is assigned because no treatment is being evaluated.
Brain Outcomes With Lifestyle Change in Down Syndrome
This trial is testing whether weight loss through a reduced-calorie diet can help protect the brains of adults with Down syndrome who do not yet have dementia. Half of participants will follow a structured diet program; the other half will receive general health education. Researchers will track cognition, brain imaging, and blood markers over 12 months. This is a Phase NA behavioral study, meaning it is evaluating a lifestyle approach rather than a drug.
Online Interplay Between Deciding and Acting With Mild Cognitive Impairment
This study is watching how people with mild cognitive impairment make decisions and move their arms at the same time — specifically how quickly the brain coordinates deciding and acting. Researchers are tracking reaching movements to find early biological markers of cognitive decline. This is a Phase NA study, meaning it is observational research, not a drug or treatment trial. No intervention is being tested for effectiveness.
ADRC Clinical Cohort (Alzheimer's Disease)
This is an observational research cohort at Duke and UNC, not a treatment trial. Researchers are enrolling people ages 25 to 80, with or without memory concerns, to track cognition over time and collect blood, urine, spinal fluid, and brain imaging. The goal is to understand how genes, lifestyle, and environment influence Alzheimer's risk as people age. There is no drug or intervention involved — just research observation and sample collection.
PROMIS and Mobility Evaluation in Sarcoma Patients
This study is testing whether a smartphone app can reliably track recovery in sarcoma patients after surgery. Participants complete digital questionnaires and the app passively monitors movement like step count and gait. Researchers want to see if these tools accurately capture how patients are doing over the year following surgery. The phase is unspecified, so this appears to be a validation and feasibility study rather than a drug or treatment trial.
TabCAT Brain Health Assessment in Primary Care
This trial is testing a tablet-based brain health screening tool called TabCAT in primary care clinics. The goal is to see whether using it leads to better detection of cognitive impairment and dementia compared to usual care. It is a pragmatic trial, meaning it runs in real clinic settings rather than a controlled lab. Phase NA here means it is not a drug trial — it is evaluating a clinical workflow tool.
Developing Risk Prediction Model and Testing the Effect of Dual Task Walking on Improving Cognitive Function in Patients With Colorectal Cancer
This trial tests whether dual-task walking — walking while simultaneously doing a mental exercise — can help preserve or improve cognitive function in colorectal cancer patients. Researchers also want to build a model to predict who is at risk for cancer-related cognitive decline. This is a Phase NA behavioral study, meaning it is exploring an intervention approach rather than testing a drug.
Evaluation Study for the Chef Anchor 3.0 Program
This trial is testing a 10-week cooking program called Chef Anchor 3.0 for older adults with mild cognitive impairment or dementia and their caregivers. Researchers want to see whether the program improves cooking confidence, independence, psychological well-being, and cognitive function — and whether those gains last. This is a Phase NA study, meaning it is a practical evaluation of an existing program rather than a traditional drug trial.
Language and Lewy Body Diseases: Sentence Comprehension Problems and Modifying Noninvasive Brain Stimulation Treatment
This trial is testing whether a mild electrical brain stimulation technique called tDCS can help people with Lewy body diseases, specifically Parkinson's disease or dementia with Lewy bodies, who have language and comprehension difficulties. Researchers will first map how language breaks down in these patients, then see if home-based brain stimulation can help. This is a Phase NA, or non-standard phase, exploratory study, meaning it is early-stage and aimed at understanding the problem and testing feasibility, not proving a treatment works.
A Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants
This trial is testing a new oral drug called AS-S603, made by Amyloid Solution Inc., which is designed to break up the amyloid-beta and tau protein clumps associated with Alzheimer's disease. Right now researchers are only checking whether it is safe and how the body processes it — this is Phase 1, the earliest human testing stage, not yet testing whether it actually works against Alzheimer's.
The Feasibility and the Efficacy of the Full-immersive Virtual Reality Cognitive Training in Patients With Mild or Moderate Dementia
This trial is testing a fully immersive virtual reality program designed to train and stimulate cognition in people who already have mild to moderate dementia. Participants wear a VR headset and complete leisure-based cognitive activities across 15 sessions over five weeks. Researchers are measuring changes in cognitive function, daily living skills, and quality of life. This is a Phase NA feasibility and efficacy study — early-stage work to see whether the approach is practical and shows promise, not a proven treatment.
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
This trial is testing a blood test called Quest AD-Detect on patients who are already hospitalized with sudden confusion or cognitive symptoms. The question is whether this blood test can spot underlying Alzheimer's disease earlier, while the patient is still in the hospital, rather than missing it during an acute illness. This is a Phase NA study, meaning it is a practical diagnostic evaluation rather than a drug or treatment trial.
TMS for Cognitive Decline in Aging and Preclinical AD
This trial is testing whether repetitive Transcranial Magnetic Stimulation — a non-invasive device that uses magnetic pulses to gently stimulate targeted brain areas — can improve motivation, memory, and brain-network function in cognitively normal older adults and people with preclinical Alzheimer's disease. Participants receive 20 sessions of either real or sham stimulation over several weeks, with MRI scans measuring what changes. This is a Phase NA designation, meaning it is a device feasibility and effects study, not a drug trial.
A Socio-Technological Intervention in Community-Based Healthcare for Individuals With Mild Cognitive Impairment (DHEAL-COM-MCI)
This trial is testing a socio-technical program for older adults with mild cognitive impairment. The program combines cognitive stimulation exercises, technology tools, and robotics to see whether it can slow cognitive decline and support well-being. It is a Phase NA study, meaning this is a practical intervention trial rather than a traditional drug development phase. Details on exact technology used are limited in the source.
EVASION: Effect of VisuAl Stimulation on attentION
This trial is testing whether a visual brain-training software called Emeraude helps people with a specific type of mild cognitive impairment — the kind that affects planning and mental flexibility — process information faster. Participants either do daily visual cognitive exercises or watch TV for 30 days. Researchers also track memory, walking ability, and quality of life. This is a Phase NA trial, meaning it is more of a structured feasibility or exploratory study than a large efficacy trial.
Advances in Telephone-based Cognitive Screening Procedures
This Italian observational study is testing whether cognitive screening done by telephone works as well as standard in-person testing for people with neurological conditions like Alzheimer's, ALS, Lewy body dementia, and others. Researchers want to validate phone-based tools and create conversion formulas between telephone and paper tests. This is not a treatment trial — no phase is assigned because no drug or device is being tested.
Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment
This trial is testing NANO-PSO, a pomegranate seed oil supplement, to see whether it improves memory and thinking in older adults who already have mild to moderate cognitive impairment consistent with Alzheimer's disease. Participants take two capsules daily for six months, then researchers compare results against a placebo group. This is a Phase 2 trial, meaning researchers are testing whether it shows a meaningful effect and is safe — it is not yet proven or approved.
Transcranial Magnetic Stimulation for MCI
This trial is testing a non-invasive brain stimulation technique called accelerated TMS (transcranial magnetic stimulation) in people who have both mild cognitive impairment and depression. Researchers want to find the right dose before moving to larger studies. It is a Phase NA device study — meaning it is dose-finding work, not yet a full efficacy test. Half the participants receive real stimulation; half receive a sham version.
Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease
This study collects biological samples — blood, urine, stool, saliva, and tongue coating — from people with mild cognitive impairment or Alzheimer's disease, then analyzes proteins in those samples using a laboratory technique called LC-MS/MS. The goal is to find protein patterns that might signal early disease. This is an observational study with no phase designation — no drug or treatment is being tested.
DRIVing Simulator and People With NeuroCognitive Disorders
This study uses a driving simulator to measure how well people with neurocognitive disorders — such as mild cognitive impairment or dementia — can drive and, crucially, how accurately they judge their own driving ability. Researchers will compare simulator performance and self-awareness scores between people with NCDs and a healthy control group. There is no phase designation; this is an observational, exploratory study with no drug or treatment involved.
The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders
This trial tests DANCEREX-DTx, a digital app that guides people through dance and music-based exercise sessions designed for brain and neurological health. Participants are randomly assigned to the full app experience, dance-only sessions, or an educational program. Researchers want to know whether the digital motivational layer improves how consistently people stick with the program. This is a proof-of-concept study, meaning it is an early-stage test of feasibility and initial effectiveness, not a proven treatment.
Biomarker Exploration in Aging, Cognition and Neurodegeneration
This observational study is tracking brain changes in people 60 and older who currently have normal cognition. Researchers are using MRI, amyloid PET, tau PET, and cognitive testing to see which early brain changes best predict future memory decline. There is no drug treatment involved — this is a measurement and monitoring study. Phase 3 here means the imaging and testing methods are being validated at a larger scale, not that a therapy is being tested.
Longitudinal Study Examining At-Home tDCS
This study follows people with Alzheimer's or other dementia who choose to use a tDCS device at home on their own. tDCS delivers a mild electrical current to the scalp. Researchers are not assigning the treatment — participants have already decided to use it themselves. The team advises them on setup, trains them, and collects monthly reports for at least two years. This is a Phase NA observational study, meaning it is tracking real-world use rather than running a controlled experiment.
Closed-Loop Brain Stimulation as a Potential Intervention for Cognitive Decline
This trial tests a brain stimulation technique called theta burst stimulation, or TBS, delivered through a helmet-like device placed on the scalp. Participants play a cognitive video game while the system monitors their brainwaves in real time and triggers stimulation when attention flags. The goal is to see whether this approach can improve cognitive control in people with mild cognitive impairment. This is a Phase NA study, meaning it sits outside the standard drug-trial phases — think of it as a proof-of-concept device study.
Validation of an Alzheimer's Disease Marker by Fecal Assay of Amyloid Peptides and Tau Proteins
This trial is testing whether Alzheimer's-related proteins — amyloid and tau — can be detected in stool samples. The idea is that the brain may clear these toxic proteins through the gut, making a simple fecal test a possible early diagnostic tool. This is a validation study, not a treatment trial, so it is focused on proving whether the test works, not on any therapy. Details on phase are not specified.
Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease
This study is not testing a drug or treatment. Researchers in France are using a structured questionnaire to measure how much time and effort family caregivers spend supporting people with Alzheimer's at different stages of the disease. The goal is to understand how caregiver workload shifts as the disease progresses. The phase is unspecified, and this is an observational study, not a clinical intervention trial.
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
This Phase 1 study uses specialized PET brain scans to look for microglial activation — a sign of brain inflammation — in people with multiple sclerosis and Alzheimer's disease compared to healthy volunteers. It is also testing whether a newer radioactive tracer is as reliable as the current standard one. Phase 1 here means early-stage research focused on imaging accuracy and safety, not on treating any disease.
Smartphone-based Cognitive Emotion Regulation Training for Unpaid Primary Caregivers of Persons With Alzheimer's Disease
This trial tests whether a one-week smartphone-based emotion regulation program can reduce stress, depression, and caregiver burden in unpaid family caregivers of people with Alzheimer's or related dementias. Participants are randomly assigned to one of two mental reframing techniques or a control group, with follow-up over three months. This is a Phase NA behavioral study — it is testing whether the approach works, not evaluating a drug or approved therapy.
Family Interventions iN Dementia Mental Health Environments
This study is not a drug or treatment trial. It is UK-based research aimed at understanding what family carers go through when a loved one with dementia is admitted to a mental health ward. Researchers will survey wards, interview carers and staff, observe daily ward life, and use what they learn to design practical support strategies. There is no phase, because no intervention is being tested on patients.
Rifaximin SSD in Dementia Trial
This trial is testing a new low-dose formulation of rifaximin, an antibiotic that stays in the gut rather than entering the bloodstream, to see whether it can shift gut bacteria in a more favorable direction in people who already have mild to moderate Alzheimer's or vascular dementia. It is a Phase 1 trial, meaning the primary goals are safety and tolerability, not proving the treatment works.
Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia
This trial is testing whether Daphnetin, a plant-derived compound, can improve thinking and memory in people who have mild cognitive problems caused by blood vessel disease in the brain — but who have not yet developed full dementia. Participants take either Daphnetin capsules or a placebo daily for six months. It is a Phase NA trial, meaning it is likely an efficacy study but outside the standard Phase 1-3 framework, and the intervention is not yet proven or approved for this use.
AusCADASIL: An Australian Cohort of CADASIL
This study is building a long-term registry of Australians with CADASIL, a rare inherited condition that damages small blood vessels in the brain. Researchers will track symptoms, brain scans, blood markers, genetics, and cognitive testing over time to better understand how the disease progresses. This is an observational cohort study, not a treatment trial, so no drugs or interventions are being tested.
18F-mFBG Cardiac Uptake With Lewy Body Dementia
This trial is testing a radioactive imaging agent called 18F-mFBG to see how well it can detect nerve damage in the heart caused by Lewy body diseases like Parkinson's and Lewy body dementia. Researchers will compare heart scan results between people with Lewy body disease and those with other neurological conditions. This is a Phase 2 trial — testing whether the imaging tool works accurately, not a treatment study.
Brain Connectivity Marker for Alzheimer's Disease
This study is testing whether brain connectivity scans can detect early signs of Alzheimer's disease before or as symptoms develop. Researchers will use neuroimaging to look at how different brain regions communicate with each other, then track whether those patterns predict who goes on to develop AD. The phase is unspecified, meaning this appears to be an observational study rather than a drug trial.
Caring for Caregivers of Individuals With Alzheimer's Disease
The EMBRACE Study tests whether a virtual, home-based group exercise program can reduce depression and anxiety in family caregivers of people with Alzheimer's disease or related dementias. Participants use an at-home elliptical provided by the study and join weekly online sessions for three months. This is a Phase NA behavioral trial — it is evaluating whether the program is feasible and effective, not testing a drug or medical device.
Effects of Photobiomodularion on Brain Connectivity and Cognitive Function in Cognitive Impairment
This trial is testing whether shining near-infrared light on the brain — a technique called transcranial photobiomodulation — can improve memory and how brain regions talk to each other in people with amnestic mild cognitive impairment. Participants also do cognitive training, and researchers use brain scans to track changes. Phase NA here means it is a controlled feasibility or pilot study — not yet at the stage of a large proven treatment.
Persons With Dementia and Their Extended Family Caregivers
This study is not a clinical drug or device trial. Researchers are interviewing extended family caregivers of people living with dementia to learn how they manage care, what services they use, and what gets in the way. Participants do a phone interview and a short daily diary for eight days. The goal is to improve how support services are delivered to caregivers and the people they care for. No phase designation applies here.
Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs
This Phase 4 trial is testing lecanemab, an already-approved amyloid-targeting antibody drug, in patients with early-to-moderate Alzheimer's disease over 24 months. What makes it unusual is the use of multi-omics — combining eye imaging, brain MRI, blood markers, and cognitive scores to get a fuller picture of how the drug works and who it helps or harms. Phase 4 means the drug is approved; this is post-market study to deepen understanding.
PUMCH Dementia Longitudinal Cohort Study
This is an observational cohort study based at a major Chinese hospital. Researchers are following elderly Chinese patients who already have a confirmed dementia diagnosis, tracking how their condition changes over time. There is no treatment being tested. It is a data-collection effort designed to better understand how different types of dementia progress. No phase is listed because this is not a drug or device trial.
Memory and Social Interactions
This study is testing whether social settings help people with Alzheimer's disease or semantic dementia learn and remember new information better. Researchers compare three social learning contexts — being near someone, watching someone, and working together — to see which conditions support memory most. It is not a drug trial. The phase is unspecified, suggesting this is observational or early-stage research rather than a treatment study.
Impact of the Digital Multi-domain Cognitive Intervention in High-risk Populations for Dementia
This trial is testing a digital, multi-domain cognitive intervention — think structured brain-training activities delivered digitally across several cognitive areas — in older adults who already show early memory or thinking concerns (SCD or MCI). Researchers want to see whether the program slows or reduces cognitive decline in this high-risk group. This is a Phase NA behavioral study, meaning it is evaluating a non-drug program, not a medication, and is not yet a proven or approved treatment.
Early Detection of Alzheimer's Disease and Affective Disorders by Automated Voice and Speech Analysis (PLATA)
PLATA is testing whether an algorithm can detect early signs of Alzheimer's disease by analyzing how people speak during a phone-based cognitive task. Researchers will compare speech patterns against established biological markers like CSF proteins and PET scans. This is a diagnostic research study, not a clinical drug trial — the goal is to see if voice analysis could one day replace invasive testing like lumbar punctures. Details on phase are limited.
Feasibility Study of Virtual Sail 3D in Cognitive Functions
This trial is testing whether a 6-week virtual reality program called CEREBRUM, built around immersive 3D sailing scenarios, can help improve memory, attention, and other cognitive skills in older adults with mild cognitive impairment. Participants are compared against a web-based health education group. This is a feasibility study, meaning researchers are checking whether the approach is practical and safe before testing it more rigorously. No drugs are involved.
miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction
This study is collecting blood samples, and optionally cerebrospinal fluid, from people with early Alzheimer's and healthy controls. Researchers want to know whether a specific molecular pathway (miR-342-5p/AnkG) shows up in body fluids and could serve as an early detection signal. This is not a drug trial — it is a biomarker discovery study, meaning researchers are building scientific groundwork, not testing a treatment.
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
This study is testing a new digital cognitive assessment tool called IC3, designed specifically for stroke survivors. Researchers want to know whether it can reliably detect memory and thinking problems after stroke, and whether combining it with brain MRI and blood tests reveals useful markers of cognitive recovery. This is an observational study, not a drug trial — no experimental treatment is being given.
APOE4 trial pipeline
Where the trials sit in the development pipeline. Higher bars = more research underway.
Browse every APOE4 trial (1,349)
Explore the trials.
Browse APOE4-relevant Alzheimer’s trials by state or recruiting status, or start with our plain-English guide to joining one.
By state